blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2086980

EP2086980 - MACROCYCLIC PEPTIDES AS HEPATITIS C VIRUS INHIBITORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  28.10.2011
Database last updated on 15.07.2024
Most recent event   Tooltip04.10.2013Lapse of the patent in a contracting state
New state(s): HU		published on 06.11.2013  [2013/45]
Applicant(s)For all designated states
Bristol-Myers Squibb Company
Route 206 and Province Line Road
Princeton, NJ 08543 / US
[N/P]
Former [2010/51]For all designated states
Bristol-Myers Squibb Company
Route 206 and Province Line Road
Princeton, NJ 08543-4000 / US
Former [2009/33]For all designated states
Bristol-Myers Squibb Company
Route 206 and Province Line Road
Princeton NJ 08543-4000 / US
Inventor(s)01 / WANG, Alan Xiangdong
Bristol-Myers Squibb Co. 5 Research Parkway
Wallingford, Connecticut 06492 / US
02 / ZHENG, Barbara Zhizhen
Bristol-Myers Squibb Co. 5 Research Parkway
Wallingford, Connecticut 06492 / US
03 / D'ANDREA, Stanley
Bristol-Myers Squibb Co. 5 Research Parkway
Wallingford, Connecticut 06492 / US
04 / MEANWELL, Nicholas A.
Bristol-Myers Squibb Co. 5 Research Parkway
Wallingford, Connecticut 06492 / US
05 / SCOLA, Paul Michael
Bristol-Myers Squibb Co. 5 Research Parkway
Wallingford, Connecticut 06492 / US
 [2009/33]
Representative(s)Reitstötter Kinzebach
Patentanwälte
Sternwartstraße 4
81679 München / DE
[N/P]
Former [2009/33]Reitstötter - Kinzebach
Patentanwälte Sternwartstrasse 4
81679 München / DE
Application number, filing date07864438.215.11.2007
[2009/33]
WO2007US84788
Priority number, dateUS20060866125P16.11.2006         Original published format: US 866125 P
US2007093976814.11.2007         Original published format: US 939768
[2009/33]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2008064061
Date:29.05.2008
Language:EN
[2008/22]
Type: A1 Application with search report 
No.:EP2086980
Date:12.08.2009
Language:EN
The application published by WIPO in one of the EPO official languages on 29.05.2008 takes the place of the publication of the European patent application.
[2009/33]
Type: B1 Patent specification 
No.:EP2086980
Date:22.12.2010
Language:EN
[2010/51]
Search report(s)International search report - published on:EP29.05.2008
ClassificationIPC:C07K5/08, C07D487/04, C07D498/04, A61K31/407, A61P31/12
[2010/16]
CPC:
C07D487/04 (EP,US); A61P1/16 (EP); A61P31/12 (EP);
A61P31/14 (EP); A61P43/00 (EP); C07D498/04 (EP,US);
C07K5/0812 (EP,US) (-)
Former IPC [2009/33]C07D487/04, C07D498/04, A61K31/407, A61P31/12
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2009/33]
Extension statesHR11.05.2009
TitleGerman:MAKROCYCLISCHE PEPTIDE ALS HEPATITIS-C-VIRUS-HEMMER[2009/33]
English:MACROCYCLIC PEPTIDES AS HEPATITIS C VIRUS INHIBITORS[2009/33]
French:PEPTIDES MACROCYCLIQUES SERVANT D'INHIBITEURS DU VIRUS DE L'HÉPATITE C[2009/33]
Entry into regional phase11.05.2009National basic fee paid 
11.05.2009Designation fee(s) paid 
11.05.2009Examination fee paid 
Examination procedure11.05.2009Amendment by applicant (claims and/or description)
11.05.2009Examination requested  [2009/33]
06.04.2010Communication of intention to grant the patent
03.08.2010Fee for grant paid
03.08.2010Fee for publishing/printing paid
13.09.2010Despatch of a communication from the examining division (Time limit: M04)
27.09.2010Reply to a communication from the examining division
Opposition(s)23.09.2011No opposition filed within time limit [2011/48]
Fees paidRenewal fee
12.11.2009Renewal fee patent year 03
12.11.2010Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT22.12.2010
BE22.12.2010
CY22.12.2010
CZ22.12.2010
DK22.12.2010
EE22.12.2010
FI22.12.2010
HU22.12.2010
LT22.12.2010
LV22.12.2010
MT22.12.2010
NL22.12.2010
PL22.12.2010
RO22.12.2010
SE22.12.2010
SI22.12.2010
SK22.12.2010
TR22.12.2010
BG22.03.2011
GR23.03.2011
IS22.04.2011
PT22.04.2011
[2013/45]
Former [2013/44]AT22.12.2010
BE22.12.2010
CY22.12.2010
CZ22.12.2010
DK22.12.2010
EE22.12.2010
FI22.12.2010
LT22.12.2010
LV22.12.2010
MT22.12.2010
NL22.12.2010
PL22.12.2010
RO22.12.2010
SE22.12.2010
SI22.12.2010
SK22.12.2010
TR22.12.2010
BG22.03.2011
GR23.03.2011
IS22.04.2011
PT22.04.2011
Former [2013/14]AT22.12.2010
BE22.12.2010
CY22.12.2010
CZ22.12.2010
DK22.12.2010
EE22.12.2010
FI22.12.2010
LT22.12.2010
LV22.12.2010
MT22.12.2010
NL22.12.2010
PL22.12.2010
RO22.12.2010
SE22.12.2010
SI22.12.2010
SK22.12.2010
BG22.03.2011
GR23.03.2011
IS22.04.2011
PT22.04.2011
Former [2011/47]AT22.12.2010
BE22.12.2010
CY22.12.2010
CZ22.12.2010
DK22.12.2010
EE22.12.2010
FI22.12.2010
LT22.12.2010
LV22.12.2010
NL22.12.2010
PL22.12.2010
RO22.12.2010
SE22.12.2010
SI22.12.2010
SK22.12.2010
BG22.03.2011
GR23.03.2011
IS22.04.2011
PT22.04.2011
Former [2011/38]AT22.12.2010
BE22.12.2010
CY22.12.2010
CZ22.12.2010
EE22.12.2010
FI22.12.2010
LT22.12.2010
LV22.12.2010
NL22.12.2010
PL22.12.2010
RO22.12.2010
SE22.12.2010
SI22.12.2010
SK22.12.2010
BG22.03.2011
GR23.03.2011
IS22.04.2011
PT22.04.2011
Former [2011/37]AT22.12.2010
BE22.12.2010
CY22.12.2010
CZ22.12.2010
EE22.12.2010
FI22.12.2010
LT22.12.2010
LV22.12.2010
PL22.12.2010
RO22.12.2010
SE22.12.2010
SI22.12.2010
SK22.12.2010
BG22.03.2011
GR23.03.2011
IS22.04.2011
PT22.04.2011
Former [2011/35]AT22.12.2010
BE22.12.2010
CY22.12.2010
CZ22.12.2010
EE22.12.2010
FI22.12.2010
LT22.12.2010
LV22.12.2010
SE22.12.2010
SI22.12.2010
BG22.03.2011
GR23.03.2011
IS22.04.2011
PT22.04.2011
Former [2011/34]AT22.12.2010
BE22.12.2010
CY22.12.2010
FI22.12.2010
LT22.12.2010
LV22.12.2010
SE22.12.2010
SI22.12.2010
BG22.03.2011
GR23.03.2011
PT22.04.2011
Former [2011/29]AT22.12.2010
CY22.12.2010
FI22.12.2010
LT22.12.2010
LV22.12.2010
SE22.12.2010
SI22.12.2010
BG22.03.2011
Cited inInternational search[A]WO2004093798  (ENANTA PHARM INC [US], et al) [A] 1-15 * page 109 - page 114; examples 1-71; claim - *;
 [A]WO2005070955  (BOEHRINGER INGELHEIM INT [DE], et al) [A] 1-15 * page 79, line 17 - page 82, line 6; example -; claim - *;
 [A]WO2005095403  (INTERMUNE INC [US], et al) [A] 1-15* examples 1.1-3.115,8,9,39; claim -; tables 2,3,5 *
by applicantUS2005070955
    - J. ORG. CHEM., (1978), vol. 43, page 2923
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.